<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02019576</url>
  </required_header>
  <id_info>
    <org_study_id>OZM-053</org_study_id>
    <nct_id>NCT02019576</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib</brief_title>
  <official_title>A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic radiotherapy (SRT) is a newer type of focused radiation therapy that precisely
      and accurately delivers high dose radiation to a tumour, while sparing much of the nearby
      normal organs. The use of stereotactic radiotherapy results in high rates of tumour
      destruction with minimal side effects which are very well tolerated. Often stereotactic
      radiotherapy has been used to try to cure patients who have an early stage cancer which has
      not spread, but there is less experience with using it in patients with cancer which has
      spread.

      The purpose of this study is to measure how well stereotactic radiotherapy can destroy kidney
      cancer tumours which are no longer being controlled by Sunitinib and to measure how much
      longer such an approach will allow patients to stay on Sunitinib before needing to switch to
      another medication. Stereotactic radiotherapy will be used to treat only the growing tumours
      and then patients will continue with Sunitinib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate local control at one year of metastases treated with stereotactic radiotherapy in patients who present with oligo-progression while receiving first-line treatment with Sunitinib.</measure>
    <time_frame>3 years</time_frame>
    <description>Patients will have evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria. All progressing metastases sites will be amenable to stereotactic radiotherapy. The primary endpoint of local control will be defined as the absence of local failure in the irradiated site(s). Progressive enlargement will be defined as a 20% enlargement observed on two consecutive scans from baseline scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate progression free survival after stereotactic radiotherapy while continuing to receive first-line systemic therapy with Sunitinib.</measure>
    <time_frame>3 years</time_frame>
    <description>Progression free survival will be evaluated via disease assessments of radiology scans completed every three months from the time of stereotactic radiotherapy until progression is confirmed. Progressive disease will be defined as a 20% increase in RECIST 1.1 criteria measurements observed on two consecutive scans from the baseline scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the acute and late toxicity to stereotactic radiotherapy.</measure>
    <time_frame>3 years</time_frame>
    <description>Acute and late toxicities to stereotactic radiotherapy will be assessed from adverse events, vital signs and by clinically significant changes in laboratory evaluations. Adverse events will use the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. These events will be followed until resolution or for a maximum of two years, which ever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Clear Cell Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy (SRT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stereotactic radiotherapy will be administered for up to five areas of metastatic sites showing oligo-progression within the same time period. During the Sunitinib break period, stereotactic radiotherapy will be delivered in a single fraction or up to a maximum of eight fractions. The number of fractions will depend on how many sites are being irradiated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy</intervention_name>
    <description>SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if &lt; 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.</description>
    <arm_group_label>Stereotactic radiotherapy (SRT)</arm_group_label>
    <other_name>SRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years.

          2. Able and willing to provide written informed consent and to comply with the study
             procedures.

          3. Karnofsky performance status of ≥ 80%.

          4. Favorable or intermediate Heng prognostic group defined as having two or less of the
             following factors: hemoglobin &lt; LLN; serum corrected calcium &gt; ULN; Karnofsky
             performance status &lt; 80%; time from initial diagnosis to initiation of therapy &lt; 1
             year; absolute neutrophil count &gt; ULN; platelet count &gt; ULN.

          5. Histologic confirmation of renal cell carcinoma with a clear cell component.

          6. Evidence of measurable disease according to RECIST 1.1 criteria.

          7. Already receiving first-line sunitinib therapy for at least 3 months with at least one
             imaging compared to baseline (or a CT from one year prior to the date of registration
             for patients that have been on Sunitinib therapy for over one year) that shows
             response or stable disease per RECIST v1.1, in all metastatic lesions (Note: SD by
             RECIST that allows ≤ 19% increase is allowed). Prior immunotherapy including
             interferon, IL-2, and checkpoint inhibitors is allowed before Sutent.

          8. Radiographic evidence of ≤ 5 metastatic lesions progressing. Of the 5 progressing
             lesions, a maximum of 3 lesions can be in soft tissue. (Ex. If no bone metastases
             progressing: a maximum of 3 soft tissue lesions. If bone metastases progressing: a
             maximum of 5 total lesions and a maximum of 3 in soft tissue.)

          9. All progressing metastases are amenable to stereotactic radiotherapy.

         10. Each progression metastases fulfills at least 1 of the 3 following criteria for
             oligo-progression: a. Progression of an individual metastasis according to RECIST 1.1
             criteria (≥ 20% enlargement of the tumour vs. baseline or nadir, taking as reference
             the smallest diameter seen prior to starting or during first line systemic therapy and
             associated with a 5 mm minimum increase in size); b. Unambiguous development of a new
             metastatic lesion from the time of scan taken prior to starting first-line therapy
             with sunitinib; c. Progressive enlargement of a known metastasis on 2 consecutive
             imaging studies 2-3 months apart, while receiving first-line therapy with sunitinib,
             with a minimum 5 mm increase in size from baseline.

        Exclusion Criteria:

          1. Evidence of spinal cord compression.

          2. Inability to safely treat all sites of progressing metastases.

          3. Prior malignancy within the past 5 years, excluding non-melanoma skin cancer and
             in-situ cancer.

          4. Concurrent administration of other anti-cancer therapy apart from first-line
             sunitinib.

          5. Diagnosis of ataxia telangiectasia or active collagen vascular disease.

          6. Other condition, illness, psychiatric condition or laboratory abnormality that may
             increase the risk associated with study participation or stereotactic radiotherapy
             administration, or may interfere with the interpretation of study results and in the
             judgment of the investigator would make the patient inappropriate for entry into this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg A. Bjarnason, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Cheung, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georg A. Bjarnason, MD, FRCPC</last_name>
    <phone>416-480-5847</phone>
    <email>georg.bjarnason@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nesan Bandali, RN</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>82139</phone_ext>
    <email>nesan.bandali@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Lim, MD</last_name>
      <email>Gerald.Lim@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Gerald Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Heng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Patel, MD</last_name>
      <email>Samir.Patel2@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Samir Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott North, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Kollmannsberger, MD</last_name>
      <email>ckollmannsberger@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Christian Kollmannsberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manitoba CancerCare Institute</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arbind Dubey, MD</last_name>
      <email>adubey@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Piotr Czaykowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arbind Dubey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Wood, MD</last_name>
      <email>lori.wood@cdha.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Lori Wood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Derek Wilke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Swaminath, MD</last_name>
      <email>Anand.swaminath@jcc.hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Anand Swaminath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Hotte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belal Ahmad, MD</last_name>
      <email>Belal.Ahmad@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Belal Ahmad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Rodrigues, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Morgan, MD</last_name>
      <email>smorgan@Ottawahospital.on.ca</email>
    </contact>
    <investigator>
      <last_name>Scott Morgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Canil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre, Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Bjarnason, MD, FRCPC</last_name>
      <phone>416-480-5847</phone>
      <email>georg.bjarnason@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nesan Bandali, RN</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>82139</phone_ext>
      <email>nesan.bandali@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Georg Bjarnason, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Cheung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srikala Sridhar, MD</last_name>
      <email>srikala.sridhar@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Srikala Sridhar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Brade, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Cury, MD</last_name>
      <email>fabio.cury@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fabio Cury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamim Niazi, MD</last_name>
      <email>tniazi@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Tamim Niazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>December 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic renal cell carcinoma</keyword>
  <keyword>mRCC</keyword>
  <keyword>Clear cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

